Please login to the form below

Not currently logged in
Email:
Password:

FDA okays Clovis' Lynparza rival rucaparib

Analysts predict Rubraca could become a $1.5bn-plus product by 2020
FDA

Clovis Oncology has bagged FDA approval for its ovarian cancer drug Rubraca, the first direct competitor to AstraZeneca's Lynparza.

Rubraca (rucaparib) has been cleared two months earlier than expected, given the green light for use in women with advanced ovarian cancer who have been treated with two or more chemotherapies and whose tumours test positive for a gene mutation (deleterious BRCA) using a companion diagnostic.

The PARP inhibitor has previously been awarded a breakthrough designation by the FDA and - given the high unmet medical need in ovarian cancer - analysts at Credit Suisse have predicted Rubraca could become a $1.5bn-plus product by 2020, assuming it also picks up approval in some follow-up solid tumour indications such as fallopian tube and peritoneal cancer.

The early approval gives Clovis a boost as it sets off in pursuit of Lynparza (olaparib), which became the first PARP inhibitor to be launched on its debut in late 2014. AZ's drug has been approved in around 30 countries to date and sales reached $158m in the first nine months of the year.

The FDA approval is also a welcome relief for Clovis and its shareholders. The company has been pummelled in recent months after an FDA advisory panel voted against a quick approval of its lung cancer candidate rociletinib, a decision that eventually prompted the company to drop the drug.

Rubraca could face competition from not only Lynparza but also from Tesaro's highly-anticipated PARP inhibitor niraparib, which is already under regulatory review for ovarian, fallopian tube and peritoneal cancer.

According to some analysts, niraparib could benefit from a broader label than both Lynparza and Rubraca as it might get a maintenance therapy indication in the US. Lynparza was turned down for maintenance use by an FDA advisory panel last year, and can be used for maintenance in the EU only in patients with a BRCA mutation.

In trials, niraparib was able to improve progression-free survival (PFS) in recurrent ovarian cancer regardless of the patients' BRCA status.

Credit Suisse puts Lynparza sales at $1.6bn in 2020, just ahead of Rubraca, with niraparib in third place with just over $1bn in sales in that year. 

Article by
Phil Taylor

20th December 2016

From: Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Virgo Health

Virgo Health is an award-winning global healthcare communications and medical education agency comprising specialists with some of the best skills,...

Latest intelligence

BrAInPME.png
The future of medical content: The personal touch
The purpose of delivering personalised content to HCPs is not just about customer experience, it's about improving healthcare. Our Commercial Director, Tib Catania discusses what ‘deep learning’ means for the...
Rise of the patient expert - an interview with Michael Seres
Founded by Michael Seres in 2011, 11 Health is a connected medical device company currently working to change the lives of patients using stoma bags. Content Marketing Manager Liz Inskip...
Making sense of Nutraceuticals in China
Published in eyeforpharma February 2017 by Marc Yates...

Infographics